SG11201808676RA - Methods of treating pediatric cancers - Google Patents
Methods of treating pediatric cancersInfo
- Publication number
- SG11201808676RA SG11201808676RA SG11201808676RA SG11201808676RA SG11201808676RA SG 11201808676R A SG11201808676R A SG 11201808676RA SG 11201808676R A SG11201808676R A SG 11201808676RA SG 11201808676R A SG11201808676R A SG 11201808676RA SG 11201808676R A SG11201808676R A SG 11201808676RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- april
- tresser
- stamford
- blvd
- Prior art date
Links
- 208000011654 childhood malignant neoplasm Diseases 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/176744 Al 12 October 2017 (12.10.2017) WIPO I PCT 1111111111111101110111111111110101111101110101111111111111111111111111111111110111111 (51) International Patent Classification: A61K 31/519 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2017/025932 (22) International Filing Date: 4 April 2017 (04.04.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/318,041 4 April 2016 (04.04.2016) US 62/323,437 15 April 2016 (15.04.2016) US 62/329,653 29 April 2016 (29.04.2016) US 62/380,773 29 August 2016 (29.08.2016) US 62/449,366 23 January 2017 (23.01.2017) US (71) Applicant: LOXO ONCOLOGY, INC. [US/US]; 281 Tresser Blvd., 9th Floor, Stamford, Connecticut 06901 (US). (72) Inventors; and (71) Applicants : COX, Michael [US/US]; 281 Tresser Blvd., 9th Floor, Stamford, Connecticut 06901 (US). NANDA, Nisha [US/US]; 281 Tresser Blvd., 9th Floor, Stamford, Connecticut 06901 (US). (74) Agents: FOLLETT, Angela D. et al.; Fish & Richardson P.C., P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) W O 20 1717 / 67 44 Al (54) Title: METHODS OF TREATING PEDIATRIC CANCERS (57) : A method of treating a pediatric cancer in a subject in need thereof. The method includes administering to the subject a therapeutically effective amount of (S)-N-(54(R)-2-(2,5-difluorophenyppyrrolidin-l-y1)-pyrazolo[1,5-a]pyrimidin-3-y1)-3-hy- droxypyrrolidine-1-carboxamide, or a pharmaceutically acceptable salt thereof, or a combination thereof.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662318041P | 2016-04-04 | 2016-04-04 | |
| US201662323437P | 2016-04-15 | 2016-04-15 | |
| US201662329653P | 2016-04-29 | 2016-04-29 | |
| US201662380773P | 2016-08-29 | 2016-08-29 | |
| US201762449366P | 2017-01-23 | 2017-01-23 | |
| PCT/US2017/025932 WO2017176744A1 (en) | 2016-04-04 | 2017-04-04 | Methods of treating pediatric cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808676RA true SG11201808676RA (en) | 2018-11-29 |
Family
ID=58610006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808676RA SG11201808676RA (en) | 2016-04-04 | 2017-04-04 | Methods of treating pediatric cancers |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP3439663B1 (en) |
| JP (1) | JP7057343B2 (en) |
| KR (2) | KR20210010652A (en) |
| CN (1) | CN109310694A (en) |
| AU (1) | AU2017246547B2 (en) |
| BR (1) | BR112018070017A2 (en) |
| CA (1) | CA3019661A1 (en) |
| CL (1) | CL2018002807A1 (en) |
| DK (1) | DK3439663T3 (en) |
| ES (1) | ES2987501T3 (en) |
| FI (1) | FI3439663T3 (en) |
| HR (1) | HRP20241295T1 (en) |
| HU (1) | HUE068542T2 (en) |
| IL (1) | IL262005A (en) |
| LT (1) | LT3439663T (en) |
| MA (1) | MA44612B1 (en) |
| MX (1) | MX386415B (en) |
| PH (1) | PH12018502134A1 (en) |
| PL (1) | PL3439663T3 (en) |
| PT (1) | PT3439663T (en) |
| RS (1) | RS65988B1 (en) |
| RU (1) | RU2751636C2 (en) |
| SG (1) | SG11201808676RA (en) |
| SI (1) | SI3439663T1 (en) |
| TN (2) | TN2018000338A1 (en) |
| UA (1) | UA125025C2 (en) |
| WO (1) | WO2017176744A1 (en) |
| ZA (1) | ZA201806684B (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2350071T1 (en) | 2008-10-22 | 2014-05-30 | Array Biopharma, Inc. | SUBSTITUTED PYRAZOLOŠ1,5-aĆPYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS |
| SG11201803438XA (en) | 2015-10-26 | 2018-05-30 | Univ Colorado Regents | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| MX386416B (en) | 2016-04-04 | 2025-03-18 | Loxo Oncology Inc | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| FI3800189T3 (en) | 2016-05-18 | 2023-07-31 | Loxo Oncology Inc | (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)PYRROLIDIN-1-YL)PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDIN-1- PREPARATION OF CARBOXAMIDE |
| JOP20190092A1 (en) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF |
| CN109354578A (en) * | 2018-12-06 | 2019-02-19 | 浙江师范大学 | A kind of Tini intermediate and synthetic method of Tini |
| CN109593803A (en) * | 2018-12-24 | 2019-04-09 | 上海健康医学院 | (R) preparation method of -2- (2,5- difluorophenyl) pyrrolidines or its salt |
| CN110283858B (en) * | 2019-07-05 | 2024-01-26 | 尚科生物医药（上海）有限公司 | Method for preparing (S) -2- (2, 5-difluorophenyl) pyrrolidine by biocatalysis |
| CN110804059B (en) * | 2019-09-30 | 2024-03-12 | 郑州泰基鸿诺医药股份有限公司 | Carbamate compound, pharmaceutical composition and application thereof |
| CN111302997B (en) * | 2020-04-15 | 2022-03-29 | 江苏恒沛药物科技有限公司 | Method for preparing Raatinib intermediate by one-pot method |
| CN111362854B (en) * | 2020-04-30 | 2021-04-27 | 安徽德信佳生物医药有限公司 | Preparation method of ralotinib intermediate |
| CN111763211A (en) * | 2020-08-05 | 2020-10-13 | 安庆多辉生物科技有限公司 | Raatinib hydrochloride, preparation method and application |
Family Cites Families (126)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5877016A (en) | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
| US5844092A (en) | 1994-03-18 | 1998-12-01 | Genentech, Inc. | Human TRK receptors and neurotrophic factor inhibitors |
| EP1292680B1 (en) | 2000-06-22 | 2009-10-21 | Genentech, Inc. | Agonist anti-trk-c monoclonal antibodies |
| ITMI20021620A1 (en) | 2002-07-23 | 2004-01-23 | Novuspharma Spa | ANTI-TUMORAL ACTIVITY COMPOUND |
| US7514446B2 (en) | 2003-02-20 | 2009-04-07 | Smithkline Beecham Corporation | Pyrimidine compounds |
| US20060094699A1 (en) | 2003-04-11 | 2006-05-04 | Kampen Gita Camilla T | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy |
| WO2005044835A1 (en) | 2003-10-27 | 2005-05-19 | Genelabs Technologies, Inc. | METHODS FOR PREPARING 7-(2'-SUBSTITUTED-ß-D-RIBOFURANOSYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES |
| MY141220A (en) | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
| US20080312192A1 (en) | 2003-11-28 | 2008-12-18 | Guido Bold | Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases |
| US7504509B2 (en) | 2003-12-19 | 2009-03-17 | Plexxikon, Inc. | Compounds and methods for development of Ret modulators |
| WO2005068424A1 (en) | 2004-01-20 | 2005-07-28 | Cell Therapeutics Europe S.R.L. | Indolinone derivatives as receptor tyrosine kinase ihibitors |
| US20050222171A1 (en) | 2004-01-22 | 2005-10-06 | Guido Bold | Organic compounds |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| PE20060664A1 (en) | 2004-09-15 | 2006-08-04 | Novartis Ag | BICYCLE AMIDAS AS KINASE INHIBITORS |
| DE102005003687A1 (en) | 2005-01-26 | 2006-07-27 | Sphingo Tec Gmbh | Immunodiagnostic determination of neurotensin in mammal blood, comprises injecting immune active N-terminal mammal proneurotensin in to the serum- or plasma- sample |
| US7622482B2 (en) | 2005-02-16 | 2009-11-24 | Astrazeneca | Chemical compounds |
| US20090005396A1 (en) | 2005-04-27 | 2009-01-01 | Astrazeneca Ab | Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain |
| NZ564317A (en) | 2005-05-16 | 2011-01-28 | Astrazeneca Ab | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors |
| ITRM20050290A1 (en) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | USE OF MOLECULES ABLE TO INHIBIT THE BOND BETWEEN NGF AND ITS TRKA RECEPTOR AS AN EXTENDED EFFECT ANALGESICS. |
| UA95244C2 (en) | 2005-06-22 | 2011-07-25 | Плексикон, Инк. | Compounds and methods for kinase modulation, and indications therefor |
| HRP20140218T4 (en) | 2005-08-25 | 2017-06-16 | Creabilis Therapeutics S.P.A. | POLYMER CONJUGATES K-252A AND THEIR DERIVATIVES |
| WO2007057399A2 (en) | 2005-11-15 | 2007-05-24 | Boehringer Ingelheim International Gmbh | Treatment of cancer with indole derivatives |
| WO2007077435A1 (en) | 2005-12-30 | 2007-07-12 | Astex Therapeutics Limited | Pharmaceutical compounds |
| US20090227598A1 (en) | 2006-01-24 | 2009-09-10 | Buser-Doepner Carolyn A | Ret Tyrosine Kinase Inhibition |
| JP5261370B2 (en) | 2006-03-27 | 2013-08-14 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | Pyridyl and pyrimidinyl substituted pyrrole, thiophene and furan derivatives as kinase inhibitors |
| CA2652442C (en) | 2006-05-18 | 2014-12-09 | Eisai R & D Management Co., Ltd. | Antitumor agent for thyroid cancer |
| EP2067039A2 (en) | 2006-09-12 | 2009-06-10 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute for Biomedical Research | Non-neuroendocrine cancer therapy |
| KR20090073121A (en) | 2006-09-29 | 2009-07-02 | 노파르티스 아게 | Pyrazolopyrimidines as PI3 'Lipid Kinase Inhibitors |
| AU2007316417B2 (en) | 2006-11-06 | 2013-08-22 | Tolero Pharmaceuticals, Inc. | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
| WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
| PE20081581A1 (en) | 2006-12-21 | 2008-11-12 | Plexxikon Inc | PIRROLO [2,3-b] PYRIDINES COMPOUNDS AS KINASE MODULATORS |
| JP2010514695A (en) | 2006-12-21 | 2010-05-06 | プレキシコン，インコーポレーテッド | Compounds and methods for kinase regulation and indications therefor |
| US20080234267A1 (en) | 2007-03-20 | 2008-09-25 | Karen Elizabeth Lackey | Compounds and Methods of Treatment |
| JP5160637B2 (en) | 2007-05-04 | 2013-03-13 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Compounds and compositions as c-kit and PDGFR kinase inhibitors |
| KR20100031639A (en) | 2007-07-09 | 2010-03-23 | 아스트라제네카 아베 | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
| EP2170830B1 (en) | 2007-07-17 | 2014-10-15 | Plexxikon, Inc. | 2-FLUORO-BENZENESULFONAMIDE COMPOUNDS AS Raf KINASE MODULATORS |
| NZ582708A (en) | 2007-07-19 | 2012-04-27 | Schering Corp | Heterocyclic amide compounds as protein kinase inhibitors |
| KR101567763B1 (en) | 2007-07-20 | 2015-11-12 | 네르비아노 메디칼 사이언시스 에스.알.엘. | Substituted indazole derivatives active as kinase inhibitors |
| WO2009017838A2 (en) | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
| MX2010004494A (en) | 2007-10-23 | 2010-08-30 | Novartis Ag | Use of trkb antibodies for the treatment of respiratory disorders. |
| WO2009071480A2 (en) | 2007-12-04 | 2009-06-11 | Nerviano Medical Sciences S.R.L. | Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors |
| EP2235062A1 (en) | 2008-01-17 | 2010-10-06 | Irm Llc | Improved anti-trkb antibodies |
| JP2009203226A (en) | 2008-01-31 | 2009-09-10 | Eisai R & D Management Co Ltd | Receptor tyrosine kinase inhibitor containing pyridine derivative and pyrimidine derivative |
| US8207165B2 (en) | 2008-03-28 | 2012-06-26 | Nerviano Medical Sciences S.R.L. | 3,4-dihydro-2H-pyrazino[1,2-A]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| US8158636B2 (en) | 2008-05-19 | 2012-04-17 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| PE20091846A1 (en) | 2008-05-19 | 2009-12-16 | Plexxikon Inc | PIRROLO [2,3-d] -PYRIMIDINE DERIVATIVES AS KINE MODULATORS |
| WO2009141386A1 (en) | 2008-05-23 | 2009-11-26 | Novartis Ag | Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors |
| JP5767965B2 (en) | 2008-06-10 | 2015-08-26 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | 5H-pyrrolo [2,3-B] pyrazine derivatives that regulate kinases and indications thereof |
| US8946226B2 (en) | 2008-07-29 | 2015-02-03 | Nerviano Medical Sciences S.R.L. | Use of CDK inhibitor for the treatment of glioma |
| ES2536730T3 (en) | 2008-09-19 | 2015-05-28 | Nerviano Medical Sciences S.R.L. | 3,4-Dihydro-2H-pyrrolo [1,2-a] pyrazin-1-one derivatives |
| WO2010033941A1 (en) | 2008-09-22 | 2010-03-25 | Array Biopharma Inc. | Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors |
| SI2350071T1 (en) * | 2008-10-22 | 2014-05-30 | Array Biopharma, Inc. | SUBSTITUTED PYRAZOLOŠ1,5-aĆPYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS |
| US8912194B2 (en) | 2008-11-24 | 2014-12-16 | Nerviano Medical Sciences S.R.L. | CDK inhibitor for the treatment of mesothelioma |
| JO3265B1 (en) | 2008-12-09 | 2018-09-16 | Novartis Ag | Pyridyloxyindoles Inhibitors of VEGF-R2 and Use Thereof for Treatment of Disease |
| WO2010111527A1 (en) | 2009-03-26 | 2010-09-30 | Plexxikon, Inc. | Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use |
| EP2443117B1 (en) | 2009-06-15 | 2016-03-23 | Nerviano Medical Sciences S.r.l. | Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors |
| AR077468A1 (en) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS |
| WO2011092120A1 (en) | 2010-01-29 | 2011-08-04 | Nerviano Medical Sciences S.R.L. | 6,7- dihydroimidazo [1,5-a] pyrazin-8 (5h) - one derivatives as protein kinase modulators |
| TWI619713B (en) | 2010-04-21 | 2018-04-01 | 普雷辛肯公司 | Compounds and methods for kinase regulation and their indications |
| BR112012029405B1 (en) | 2010-05-20 | 2021-01-05 | Array Biopharma Inc. | macrocyclic compounds such as trk kinase inhibitors, pharmaceutical composition, use of a compound of formula i or a pharmaceutically acceptable salt thereof, process for the preparation of a compound |
| UY33597A (en) | 2010-09-09 | 2012-04-30 | Irm Llc | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF THE TRK |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| JP2014005206A (en) | 2010-10-22 | 2014-01-16 | Astellas Pharma Inc | Arylamino heterocyclic carboxamide compound |
| JP5925808B2 (en) | 2011-01-26 | 2016-05-25 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | Tricyclic derivatives, their preparation and their use as kinase inhibitors |
| RU2591191C2 (en) | 2011-01-26 | 2016-07-10 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Tricyclic pyrrole derivatives, method for production thereof and use thereof as kinase inhibitors |
| SMT201900112T1 (en) | 2011-02-07 | 2019-02-28 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| BR112013021537B1 (en) | 2011-02-24 | 2021-08-10 | Nerviano Medical Sciences S.R.L. | THAZOLYLPENYL-BENZENOSULPONAMIDE DERIVATIVES AS KINASE INHIBITORS |
| EP2678338B1 (en) | 2011-02-25 | 2015-09-09 | Novartis AG | Pyrazolo[1,5-a]pyridines as trk inhibitors |
| US9284298B2 (en) | 2011-04-11 | 2016-03-15 | Nerviano Medical Sciences S.R.L. | Pyrazolyl-pyrimidine derivatives as kinase inhibitors |
| JP5970537B2 (en) | 2011-04-19 | 2016-08-17 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | Substituted pyrimidinyl-pyrroles active as kinase inhibitors |
| JP6396210B2 (en) | 2011-05-12 | 2018-09-26 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | Substituted indazole derivatives active as kinase inhibitors |
| PL2712358T3 (en) | 2011-05-13 | 2017-05-31 | Array Biopharma, Inc. | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors |
| EP2736514B1 (en) | 2011-07-28 | 2017-10-18 | Nerviano Medical Sciences S.r.l. | Alkynyl substituted pyrimidinyl-pyrroles active as kinases inhibitors |
| ES2639064T3 (en) | 2011-10-07 | 2017-10-25 | Nerviano Medical Sciences S.R.L. | 3,4-Dihydropyrrolo [1,2-a] pyrazin-1 (2h) -one derivatives substituted as kinase inhibitors |
| WO2013050448A1 (en) | 2011-10-07 | 2013-04-11 | Nerviano Medical Sciences S.R.L. | 4-ALKYL SUBSTITUTED 3,4-DIHYDROPYRROLO[1,2-a]PYRAZIN-1(2H)-ONE DERIVATIVES AS KINASES INHIBITORS |
| WO2013059740A1 (en) | 2011-10-21 | 2013-04-25 | Foundation Medicine, Inc. | Novel alk and ntrk1 fusion molecules and uses thereof |
| AU2012339753A1 (en) | 2011-11-14 | 2014-06-19 | Tesaro, Inc. | Modulating certain tyrosine kinases |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| JP6160613B2 (en) | 2012-04-26 | 2017-07-12 | 小野薬品工業株式会社 | Trk inhibitory compound |
| NZ716487A (en) | 2012-05-23 | 2017-01-27 | Nerviano Medical Sciences Srl | Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
| TWI585088B (en) | 2012-06-04 | 2017-06-01 | 第一三共股份有限公司 | Imidazo[1,2-b]indole derivatives as kinase inhibitors |
| RU2679130C2 (en) | 2012-07-11 | 2019-02-06 | Блюпринт Медсинс Корпорейшн | Inhibitors of fibroblast growth factor receptor |
| BR112015002152B1 (en) | 2012-08-02 | 2021-04-27 | Nerviano Medical Sciences S.R.L. | COMPOUNDS OF REPLACED PYRROILS ACTIVE AS KINASE INHIBITORS, PROCESS FOR THE PREPARATION OF SUCH COMPOUNDS, PHARMACEUTICAL COMPOSITION, IN VITRO METHOD FOR INHIBITION OF THE ACTIVITY OF KINASE PROTEINS OF THE JAK FAMILY |
| ES2726605T3 (en) | 2012-09-07 | 2019-10-08 | Exelixis Inc | MET, VEGFR and RET inhibitors for use in the treatment of lung adenocarcinoma |
| EP2914621B1 (en) * | 2012-11-05 | 2023-06-07 | Foundation Medicine, Inc. | Novel ntrk1 fusion molecules and uses thereof |
| CN108047219A (en) | 2012-11-07 | 2018-05-18 | 内尔维阿诺医学科学有限公司 | Substituted pyrimidine radicals and Pyridylpyrrole and pyridinone, its preparation method and its purposes as kinase inhibitor |
| WO2014078372A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| WO2014078325A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| WO2014078378A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| WO2014078331A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| WO2014078417A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| WO2014078408A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| PL2920166T3 (en) | 2012-11-13 | 2017-05-31 | Array Biopharma, Inc. | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain |
| WO2014078328A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| WO2014078322A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| CA2890876C (en) | 2012-11-13 | 2021-01-19 | Array Biopharma Inc. | N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| MX353336B (en) | 2013-02-19 | 2018-01-09 | Ono Pharmaceutical Co | Trk-INHIBITING COMPOUND. |
| US9499522B2 (en) | 2013-03-15 | 2016-11-22 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| US8937071B2 (en) | 2013-03-15 | 2015-01-20 | Glaxosmithkline Intellectual Property Development Limited | Compounds as rearranged during transfection (RET) inhibitors |
| US9682083B2 (en) | 2013-05-14 | 2017-06-20 | Nerviano Medical Sciences S.R.L. | Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors |
| CA2912568A1 (en) | 2013-05-30 | 2014-12-04 | Plexxikon Inc. | Compounds for kinase modulation, and indications therefor |
| US10875930B2 (en) | 2013-07-30 | 2020-12-29 | Blueprint Medicines Corporation | PIK3C2G fusions |
| EP3027655B1 (en) | 2013-07-30 | 2019-08-21 | Blueprint Medicines Corporation | Ntrk2 fusions |
| WO2015039006A1 (en) * | 2013-09-16 | 2015-03-19 | The General Hospital Corporation | Methods of treating cancer |
| CA2926999C (en) | 2013-10-17 | 2021-10-19 | Blueprint Medicines Corporation | Pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-1-yl)pyrimidinyl derivatives and compositions useful for treating disorders related to kit |
| WO2015058129A1 (en) | 2013-10-17 | 2015-04-23 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| MX2016005297A (en) | 2013-10-25 | 2016-08-12 | Blueprint Medicines Corp | Inhibitors of the fibroblast growth factor receptor. |
| WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
| AP2016009383A0 (en) | 2014-01-24 | 2016-08-31 | Tp Therapeutics Inc | Diaryl macrocycles as modulators of protein kinases |
| PL3102555T3 (en) | 2014-02-05 | 2021-12-20 | VM Oncology LLC | Compositions of compounds and uses thereof |
| TWI672141B (en) | 2014-02-20 | 2019-09-21 | 美商醫科泰生技 | Molecules for administration to ros1 mutant cancer cells |
| EP3132054B1 (en) | 2014-04-18 | 2021-06-30 | Blueprint Medicines Corporation | Met fusions |
| WO2015161274A1 (en) | 2014-04-18 | 2015-10-22 | Blueprint Medicines Corporation | Pik3ca fusions |
| CN106459013B (en) | 2014-05-15 | 2019-10-25 | 阵列生物制药公司 | Compounds and uses thereof as TRKA kinase inhibitors |
| US10246750B2 (en) | 2014-06-10 | 2019-04-02 | Blueprint Medicines Corporation | Method for detection of a TECR:PKN1 or an ANXA4:PKN1 gene fusion |
| US10378063B2 (en) | 2014-06-10 | 2019-08-13 | Blueprint Medicines Corporation | RAF1 fusions |
| WO2016011147A1 (en) | 2014-07-17 | 2016-01-21 | Blueprint Medicines Corporation | Prkc fusions |
| EP3169804B3 (en) | 2014-07-17 | 2019-09-18 | Blueprint Medicines Corporation | Fgr fusions |
| US10370723B2 (en) | 2014-07-17 | 2019-08-06 | Blueprint Medicines Corporation | TERT fusions |
| WO2016022569A1 (en) | 2014-08-04 | 2016-02-11 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| ES2732026T3 (en) | 2014-08-18 | 2019-11-20 | Ono Pharmaceutical Co | Acid addition salt of a Trk inhibitor compound |
| WO2016075224A1 (en) | 2014-11-14 | 2016-05-19 | Nerviano Medical Sciences S.R.L. | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors |
| AU2015346046B2 (en) | 2014-11-16 | 2020-06-25 | Array Biopharma, Inc. | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
| EP3221700B1 (en) | 2014-11-18 | 2022-06-22 | Blueprint Medicines Corporation | Prkacb fusions |
| US20180177792A1 (en) | 2015-05-29 | 2018-06-28 | Ignyta, Inc. | Compositions and methods for treating patients with rtk mutant cells |
| SG11201803438XA (en) * | 2015-10-26 | 2018-05-30 | Univ Colorado Regents | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
-
2017
- 2017-04-04 TN TNP/2018/000338A patent/TN2018000338A1/en unknown
- 2017-04-04 JP JP2019502548A patent/JP7057343B2/en active Active
- 2017-04-04 UA UAA201809924A patent/UA125025C2/en unknown
- 2017-04-04 RU RU2018138579A patent/RU2751636C2/en active
- 2017-04-04 PL PL17719086.5T patent/PL3439663T3/en unknown
- 2017-04-04 WO PCT/US2017/025932 patent/WO2017176744A1/en not_active Ceased
- 2017-04-04 FI FIEP17719086.5T patent/FI3439663T3/en active
- 2017-04-04 AU AU2017246547A patent/AU2017246547B2/en active Active
- 2017-04-04 EP EP17719086.5A patent/EP3439663B1/en active Active
- 2017-04-04 RS RS20241058A patent/RS65988B1/en unknown
- 2017-04-04 MX MX2018012165A patent/MX386415B/en unknown
- 2017-04-04 CN CN201780021811.1A patent/CN109310694A/en active Pending
- 2017-04-04 MA MA44612A patent/MA44612B1/en unknown
- 2017-04-04 LT LTEPPCT/US2017/025932T patent/LT3439663T/en unknown
- 2017-04-04 ES ES17719086T patent/ES2987501T3/en active Active
- 2017-04-04 BR BR112018070017A patent/BR112018070017A2/en not_active Application Discontinuation
- 2017-04-04 DK DK17719086.5T patent/DK3439663T3/en active
- 2017-04-04 SI SI201731550T patent/SI3439663T1/en unknown
- 2017-04-04 CA CA3019661A patent/CA3019661A1/en active Pending
- 2017-04-04 KR KR1020217001785A patent/KR20210010652A/en not_active Ceased
- 2017-04-04 TN TNP/2019/000332A patent/TN2019000332A1/en unknown
- 2017-04-04 KR KR1020187032062A patent/KR20180129911A/en not_active Ceased
- 2017-04-04 HR HRP20241295TT patent/HRP20241295T1/en unknown
- 2017-04-04 PT PT177190865T patent/PT3439663T/en unknown
- 2017-04-04 HU HUE17719086A patent/HUE068542T2/en unknown
- 2017-04-04 SG SG11201808676RA patent/SG11201808676RA/en unknown
-
2018
- 2018-09-27 IL IL262005A patent/IL262005A/en unknown
- 2018-10-02 CL CL2018002807A patent/CL2018002807A1/en unknown
- 2018-10-03 PH PH12018502134A patent/PH12018502134A1/en unknown
- 2018-10-08 ZA ZA2018/06684A patent/ZA201806684B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| SG11201908598PA (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201903487SA (en) | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201906885TA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201811225RA (en) | Ar+ breast cancer treatment methods | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201811559WA (en) | Cancer treatment combinations | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201807597UA (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201803915UA (en) | Echinomycin formulation, method of making and method of use thereof | |
| SG11201805755SA (en) | Methods of administering hepcidin | |
| SG11201804587QA (en) | Isoindole compounds | |
| SG11201906164RA (en) | Bicyclic inhibitors of histone deacetylase |